Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

HROW vs SGHT vs ATRC vs LNTH vs MDT

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
HROW
Harrow Health, Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • US
Market Cap$1.45B
5Y Perf.+337.8%
SGHT
Sight Sciences, Inc.

Medical - Devices

HealthcareNASDAQ • US
Market Cap$286M
5Y Perf.-85.7%
ATRC
AtriCure, Inc.

Medical - Instruments & Supplies

HealthcareNASDAQ • US
Market Cap$1.41B
5Y Perf.-67.1%
LNTH
Lantheus Holdings, Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • US
Market Cap$5.92B
5Y Perf.+247.7%
MDT
Medtronic plc

Medical - Devices

HealthcareNYSE • IE
Market Cap$99.94B
5Y Perf.-40.6%

HROW vs SGHT vs ATRC vs LNTH vs MDT — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
HROW logoHROW
SGHT logoSGHT
ATRC logoATRC
LNTH logoLNTH
MDT logoMDT
IndustryDrug Manufacturers - Specialty & GenericMedical - DevicesMedical - Instruments & SuppliesDrug Manufacturers - Specialty & GenericMedical - Devices
Market Cap$1.45B$286M$1.41B$5.92B$99.94B
Revenue (TTM)$272M$80M$552M$1.55B$35.48B
Net Income (TTM)$-5M$-37M$-5M$279M$4.61B
Gross Margin75.1%86.2%75.5%60.5%61.9%
Operating Margin11.2%-44.8%-0.4%18.8%17.9%
Forward P/E82.9x370.7x17.5x14.1x
Total Debt$252M$41M$88M$738K$28.52B
Cash & Equiv.$73M$92M$167M$359M$2.22B

HROW vs SGHT vs ATRC vs LNTH vs MDTLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

HROW
SGHT
ATRC
LNTH
MDT
StockJul 21May 26Return
Harrow Health, Inc. (HROW)100437.8+337.8%
Sight Sciences, Inc. (SGHT)10014.3-85.7%
AtriCure, Inc. (ATRC)10032.9-67.1%
Lantheus Holdings, … (LNTH)100347.7+247.7%
Medtronic plc (MDT)10059.4-40.6%

Price return only. Dividends and distributions are not included.

Quick Verdict: HROW vs SGHT vs ATRC vs LNTH vs MDT

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: MDT leads in 4 of 7 categories (5-stock set), making it the strongest pick for valuation and capital efficiency and capital preservation and lower volatility. Harrow Health, Inc. is the stronger pick specifically for growth and revenue expansion. SGHT and LNTH also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
HROW
Harrow Health, Inc.
The Growth Play

HROW is the #2 pick in this set and the best alternative if growth exposure is your priority.

  • Rev growth 36.4%, EPS growth 71.4%, 3Y rev CAGR 45.4%
  • 36.4% revenue growth vs SGHT's -3.1%
Best for: growth exposure
SGHT
Sight Sciences, Inc.
The Momentum Pick

SGHT ranks third and is worth considering specifically for momentum.

  • +85.0% vs ATRC's -8.3%
Best for: momentum
ATRC
AtriCure, Inc.
The Healthcare Pick

Among these 5 stocks, ATRC doesn't own a clear edge in any measured category.

Best for: healthcare exposure
LNTH
Lantheus Holdings, Inc.
The Long-Run Compounder

LNTH is the clearest fit if your priority is long-term compounding and sleep-well-at-night.

  • 41.9% 10Y total return vs HROW's 9.1%
  • Lower volatility, beta 0.47, Low D/E 0.1%, current ratio 2.70x
  • Beta 0.47, current ratio 2.70x
  • 18.0% margin vs SGHT's -46.8%
Best for: long-term compounding and sleep-well-at-night
MDT
Medtronic plc
The Income Pick

MDT carries the broadest edge in this set and is the clearest fit for income & stability.

  • Dividend streak 36 yrs, beta 0.47, yield 3.6%
  • Lower P/E (14.1x vs 370.7x)
  • Beta 0.47 vs SGHT's 2.49, lower leverage
  • 3.6% yield; 36-year raise streak; the other 4 pay no meaningful dividend
Best for: income & stability
See the full category breakdown
CategoryWinnerWhy
GrowthHROW logoHROW36.4% revenue growth vs SGHT's -3.1%
ValueMDT logoMDTLower P/E (14.1x vs 370.7x)
Quality / MarginsLNTH logoLNTH18.0% margin vs SGHT's -46.8%
Stability / SafetyMDT logoMDTBeta 0.47 vs SGHT's 2.49, lower leverage
DividendsMDT logoMDT3.6% yield; 36-year raise streak; the other 4 pay no meaningful dividend
Momentum (1Y)SGHT logoSGHT+85.0% vs ATRC's -8.3%
Efficiency (ROA)MDT logoMDT175.8% ROA vs SGHT's -32.2%, ROIC 6.0% vs -274.4%

HROW vs SGHT vs ATRC vs LNTH vs MDT — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

HROWHarrow Health, Inc.
FY 2025
Product Sales Net
99.9%$272M
Other Revenues
0.1%$394,000
SGHTSight Sciences, Inc.
FY 2025
Surgical Glaucoma
97.9%$76M
Dry Eye
2.1%$2M
ATRCAtriCure, Inc.
FY 2025
Shipping and Handling
100.0%$2M
LNTHLantheus Holdings, Inc.
FY 2025
Product
33.4%$1.5B
Radiopharmaceutical Oncology
21.9%$989M
PYLARIFY
21.9%$989M
Total Precision Diagnostics
10.9%$493M
DEFINITY
7.3%$330M
Techne Lite
1.9%$87M
Strategic Partnerships And Other
1.3%$59M
Other (2)
1.3%$59M
MDTMedtronic plc
FY 2025
Cardiac and Vascular Group
37.3%$12.5B
Neuroscience Group
29.4%$9.8B
Medical Surgical
25.1%$8.4B
Diabetes Group
8.2%$2.8B

HROW vs SGHT vs ATRC vs LNTH vs MDT — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLMDTLAGGINGATRC

Income & Cash Flow (Last 12 Months)

Evenly matched — HROW and LNTH each lead in 2 of 6 comparable metrics.

MDT is the larger business by revenue, generating $35.5B annually — 446.0x SGHT's $80M. LNTH is the more profitable business, keeping 18.0% of every revenue dollar as net income compared to SGHT's -46.8%. On growth, HROW holds the edge at +33.3% YoY revenue growth, suggesting stronger near-term business momentum.

MetricHROW logoHROWHarrow Health, In…SGHT logoSGHTSight Sciences, I…ATRC logoATRCAtriCure, Inc.LNTH logoLNTHLantheus Holdings…MDT logoMDTMedtronic plc
RevenueTrailing 12 months$272M$80M$552M$1.5B$35.5B
EBITDAEarnings before interest/tax$59M-$35M$13M$347M$9.4B
Net IncomeAfter-tax profit-$5M-$37M-$5M$279M$4.6B
Free Cash FlowCash after capex$73M-$25M$54M$372M$5.4B
Gross MarginGross profit ÷ Revenue+75.1%+86.2%+75.5%+60.5%+61.9%
Operating MarginEBIT ÷ Revenue+11.2%-44.8%-0.4%+18.8%+17.9%
Net MarginNet income ÷ Revenue-1.9%-46.8%-0.8%+18.0%+13.0%
FCF MarginFCF ÷ Revenue+26.8%-31.9%+9.7%+24.0%+15.2%
Rev. Growth (YoY)Latest quarter vs prior year+33.3%+12.5%+14.3%+1.2%+8.8%
EPS Growth (YoY)Latest quarter vs prior year-5.3%+14.3%+101.6%+76.5%-11.9%
Evenly matched — HROW and LNTH each lead in 2 of 6 comparable metrics.

Valuation Metrics

MDT leads this category, winning 3 of 6 comparable metrics.

At 21.6x trailing earnings, MDT trades at a 19% valuation discount to LNTH's 26.7x P/E. On an enterprise value basis, MDT's 14.3x EV/EBITDA is more attractive than ATRC's 77.7x.

MetricHROW logoHROWHarrow Health, In…SGHT logoSGHTSight Sciences, I…ATRC logoATRCAtriCure, Inc.LNTH logoLNTHLantheus Holdings…MDT logoMDTMedtronic plc
Market CapShares × price$1.5B$286M$1.4B$5.9B$99.9B
Enterprise ValueMkt cap + debt − cash$1.6B$235M$1.3B$5.6B$126.2B
Trailing P/EPrice ÷ TTM EPS-278.93x-7.15x-115.83x26.69x21.60x
Forward P/EPrice ÷ next-FY EPS est.82.86x370.67x17.52x14.13x
PEG RatioP/E ÷ EPS growth rate36.00x
EV / EBITDAEnterprise value multiple77.75x14.61x14.32x
Price / SalesMarket cap ÷ Revenue5.34x3.69x2.63x3.84x2.98x
Price / BookPrice ÷ Book value/share27.56x4.31x2.70x5.72x2.08x
Price / FCFMarket cap ÷ FCF29.15x16.73x19.28x
MDT leads this category, winning 3 of 6 comparable metrics.

Profitability & Efficiency

LNTH leads this category, winning 7 of 9 comparable metrics.

LNTH delivers a 24.3% return on equity — every $100 of shareholder capital generates $24 in annual profit, vs $-59 for SGHT. LNTH carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to HROW's 4.84x. On the Piotroski fundamental quality scale (0–9), MDT scores 6/9 vs HROW's 4/9, reflecting solid financial health.

MetricHROW logoHROWHarrow Health, In…SGHT logoSGHTSight Sciences, I…ATRC logoATRCAtriCure, Inc.LNTH logoLNTHLantheus Holdings…MDT logoMDTMedtronic plc
ROE (TTM)Return on equity-10.1%-59.1%-1.0%+24.3%+9.4%
ROA (TTM)Return on assets-1.4%-32.2%-0.7%+12.4%+175.8%
ROICReturn on invested capital+9.5%-2.7%-0.6%+30.6%+6.0%
ROCEReturn on capital employed+10.2%-32.0%-0.6%+17.1%+7.5%
Piotroski ScoreFundamental quality 0–945556
Debt / EquityFinancial leverage4.84x0.64x0.18x0.00x0.59x
Net DebtTotal debt minus cash$179M-$51M-$79M-$358M$26.3B
Cash & Equiv.Liquid assets$73M$92M$167M$359M$2.2B
Total DebtShort + long-term debt$252M$41M$88M$738,000$28.5B
Interest CoverageEBIT ÷ Interest expense0.53x-14.04x0.47x11.72x9.08x
LNTH leads this category, winning 7 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

HROW leads this category, winning 3 of 6 comparable metrics.

A $10,000 investment in HROW five years ago would be worth $47,797 today (with dividends reinvested), compared to $1,579 for SGHT. Over the past 12 months, SGHT leads with a +85.0% total return vs ATRC's -8.3%. The 3-year compound annual growth rate (CAGR) favors HROW at 12.7% vs SGHT's -20.5% — a key indicator of consistent wealth creation.

MetricHROW logoHROWHarrow Health, In…SGHT logoSGHTSight Sciences, I…ATRC logoATRCAtriCure, Inc.LNTH logoLNTHLantheus Holdings…MDT logoMDTMedtronic plc
YTD ReturnYear-to-date-21.8%-29.3%-29.2%+35.3%-18.1%
1-Year ReturnPast 12 months+58.8%+85.0%-8.3%+13.1%-2.8%
3-Year ReturnCumulative with dividends+43.0%-49.7%-41.8%-4.0%-4.2%
5-Year ReturnCumulative with dividends+378.0%-84.2%-64.2%+314.2%-27.7%
10-Year ReturnCumulative with dividends+914.3%-84.2%+95.1%+4192.5%+26.5%
CAGR (3Y)Annualised 3-year return+12.7%-20.5%-16.5%-1.4%-1.4%
HROW leads this category, winning 3 of 6 comparable metrics.

Risk & Volatility

Evenly matched — LNTH and MDT each lead in 1 of 2 comparable metrics.

MDT is the less volatile stock with a 0.47 beta — it tends to amplify market swings less than SGHT's 2.49 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LNTH currently trades 97.8% from its 52-week high vs SGHT's 57.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricHROW logoHROWHarrow Health, In…SGHT logoSGHTSight Sciences, I…ATRC logoATRCAtriCure, Inc.LNTH logoLNTHLantheus Holdings…MDT logoMDTMedtronic plc
Beta (5Y)Sensitivity to S&P 5002.13x2.49x1.03x0.47x0.47x
52-Week HighHighest price in past year$54.85$9.24$43.18$93.00$106.33
52-Week LowLowest price in past year$21.12$2.81$26.62$47.25$77.16
% of 52W HighCurrent price vs 52-week peak+71.2%+57.3%+64.4%+97.8%+73.3%
RSI (14)Momentum oscillator 0–10054.654.245.061.227.3
Avg Volume (50D)Average daily shares traded733K357K669K886K7.8M
Evenly matched — LNTH and MDT each lead in 1 of 2 comparable metrics.

Analyst Outlook

MDT leads this category, winning 1 of 1 comparable metric.

Analyst consensus: HROW as "Buy", SGHT as "Buy", ATRC as "Buy", LNTH as "Buy", MDT as "Buy". Consensus price targets imply 93.8% upside for HROW (target: $76) vs 11.0% for LNTH (target: $101). MDT is the only dividend payer here at 3.57% yield — a key consideration for income-focused portfolios.

MetricHROW logoHROWHarrow Health, In…SGHT logoSGHTSight Sciences, I…ATRC logoATRCAtriCure, Inc.LNTH logoLNTHLantheus Holdings…MDT logoMDTMedtronic plc
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuyBuy
Price TargetConsensus 12-month target$75.67$9.67$50.67$101.00$109.50
# AnalystsCovering analysts109191749
Dividend YieldAnnual dividend ÷ price+3.6%
Dividend StreakConsecutive years of raises0036
Dividend / ShareAnnual DPS$2.78
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%+0.8%+5.1%+3.2%
MDT leads this category, winning 1 of 1 comparable metric.
Key Takeaway

MDT leads in 2 of 6 categories (Valuation Metrics, Analyst Outlook). LNTH leads in 1 (Profitability & Efficiency). 2 tied.

Best OverallMedtronic plc (MDT)Leads 2 of 6 categories
Loading custom metrics...

HROW vs SGHT vs ATRC vs LNTH vs MDT: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is HROW or SGHT or ATRC or LNTH or MDT a better buy right now?

For growth investors, Harrow Health, Inc.

(HROW) is the stronger pick with 36. 4% revenue growth year-over-year, versus -3. 1% for Sight Sciences, Inc. (SGHT). Medtronic plc (MDT) offers the better valuation at 21. 6x trailing P/E (14. 1x forward), making it the more compelling value choice. Analysts rate Harrow Health, Inc. (HROW) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — HROW or SGHT or ATRC or LNTH or MDT?

On trailing P/E, Medtronic plc (MDT) is the cheapest at 21.

6x versus Lantheus Holdings, Inc. at 26. 7x. On forward P/E, Medtronic plc is actually cheaper at 14. 1x.

03

Which is the better long-term investment — HROW or SGHT or ATRC or LNTH or MDT?

Over the past 5 years, Harrow Health, Inc.

(HROW) delivered a total return of +378. 0%, compared to -84. 2% for Sight Sciences, Inc. (SGHT). Over 10 years, the gap is even starker: LNTH returned +41. 9% versus SGHT's -84. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — HROW or SGHT or ATRC or LNTH or MDT?

By beta (market sensitivity over 5 years), Medtronic plc (MDT) is the lower-risk stock at 0.

47β versus Sight Sciences, Inc. 's 2. 49β — meaning SGHT is approximately 434% more volatile than MDT relative to the S&P 500. On balance sheet safety, Lantheus Holdings, Inc. (LNTH) carries a lower debt/equity ratio of 0% versus 5% for Harrow Health, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — HROW or SGHT or ATRC or LNTH or MDT?

By revenue growth (latest reported year), Harrow Health, Inc.

(HROW) is pulling ahead at 36. 4% versus -3. 1% for Sight Sciences, Inc. (SGHT). On earnings-per-share growth, the picture is similar: AtriCure, Inc. grew EPS 74. 7% year-over-year, compared to -21. 8% for Lantheus Holdings, Inc.. Over a 3-year CAGR, HROW leads at 45. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — HROW or SGHT or ATRC or LNTH or MDT?

Lantheus Holdings, Inc.

(LNTH) is the more profitable company, earning 15. 2% net margin versus -49. 7% for Sight Sciences, Inc. — meaning it keeps 15. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LNTH leads at 20. 2% versus -48. 0% for SGHT. At the gross margin level — before operating expenses — SGHT leads at 86. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is HROW or SGHT or ATRC or LNTH or MDT more undervalued right now?

On forward earnings alone, Medtronic plc (MDT) trades at 14.

1x forward P/E versus 370. 7x for AtriCure, Inc. — 356. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for HROW: 93. 8% to $75. 67.

08

Which pays a better dividend — HROW or SGHT or ATRC or LNTH or MDT?

In this comparison, MDT (3.

6% yield) pays a dividend. HROW, SGHT, ATRC, LNTH do not pay a meaningful dividend and should not be held primarily for income.

09

Is HROW or SGHT or ATRC or LNTH or MDT better for a retirement portfolio?

For long-horizon retirement investors, Medtronic plc (MDT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

47), 3. 6% yield). Sight Sciences, Inc. (SGHT) carries a higher beta of 2. 49 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MDT: +26. 5%, SGHT: -84. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between HROW and SGHT and ATRC and LNTH and MDT?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: HROW is a small-cap high-growth stock; SGHT is a small-cap quality compounder stock; ATRC is a small-cap quality compounder stock; LNTH is a small-cap quality compounder stock; MDT is a mid-cap income-oriented stock. MDT pays a dividend while HROW, SGHT, ATRC, LNTH do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

HROW

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 16%
  • Gross Margin > 45%
Run This Screen
Stocks Like

SGHT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 6%
  • Gross Margin > 51%
Run This Screen
Stocks Like

ATRC

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 7%
  • Gross Margin > 45%
Run This Screen
Stocks Like

LNTH

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 10%
Run This Screen
Stocks Like

MDT

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 7%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform HROW and SGHT and ATRC and LNTH and MDT on the metrics below

Revenue Growth>
%
(HROW: 33.3% · SGHT: 12.5%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.